Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
xeligekimab pegol
- Development stage
- Unknown
- Lead developer
- Zhixiang Jintai
- Modality
- Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
Xeligekimab pegol (GR1501) is a PEGylated recombinant humanized monoclonal antibody that targets interleukin-17A (IL-17A). By binding to IL-17A, it prevents the cytokine from interacting with its receptor, thereby inhibiting the pro-inflammatory signaling pathways that drive the pathogenesis of autoimmune and inflammatory diseases. The addition of a polyethylene glycol (PEG) moiety is intended to extend the drug's half-life and reduce the frequency of administration. It is primarily being developed for the treatment of moderate to severe plaque psoriasis and ankylosing spondylitis.
- Other names
- xeligekimabpegylated xeligekimab
02
Targets
IL-17A (Interleukin-17A)
Beyond the preview
Go deeper on xeligekimab pegol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on xeligekimab pegol.